Suzhou Yushi Pharmaceutical Co Ltd.

Main study objectives: To study the pharmacokinetics of the test preparation valsartan amlodipine tablets (I) (specification: each tablet contains 80 mg valsartan and 5 mg amlodipine, produced by Suzhou Yushi Pharmaceutical Co., Ltd.) and the reference preparation valsartan amlodipine tablets (I) (Bebot®, specification: each tablet contains 80 mg valsartan and 5 mg amlodipine, produced by Siegfried Barbera S.L., licensed by Novartis Pharma Schweiz AG) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary study objectives: To study the safety of the test preparation valsartan amlodipine tablets (I) and the reference preparation valsartan amlodipine tablets (I) (Bebot®) in healthy adult subjects after a single oral administration in the fasting and fed state.

Main study objectives To study the pharmacokinetics of the test preparation levamlodipine besylate tablets (specification: 5mg, produced by Suzhou Yushi Pharmaceutical Co., Ltd.) and the reference preparation amlodipine besylate tablets (Norvasc®; specification: 10mg; licensee: Pfizer Pharmaceuticals Co., Ltd.) in healthy adult subjects in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary study objectives To evaluate the safety of the test preparation levamlodipine besylate tablets and the reference preparation amlodipine besylate tablets (Norvasc®) in healthy Chinese subjects in the fasting and fed state.